secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018835
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Q3 2023 net loss $3.8M; cash $25.8M; DA-1241 Phase 2a first patient dosed
--------------------------------------------------------------------------------

- Net loss $3.8M in Q3 2023 (EPS -$0.09) compared to net loss $3.1M (EPS -$3.50) in Q3 2022.
- Cash and cash equivalents $25.8M as of Sep 30, 2023; expected to fund operations into Q4 2024.
- First patient dosed in Phase 2a trial of DA-1241 for NASH; interim data expected H1 2024, full data H2 2024.
- DA-1726 IND submission for obesity expected by year-end 2023; Phase 1a initiation targeted H1 2024.
- Appointed James P. Tursi, M.D. to Board of Directors in November 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/0001558370-23-018835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023018835/nrbo-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer